Microbot Medical Stock Fundamentals
| MBOT Stock | USD 0.97 0.02 2.02% |
Microbot Medical fundamentals help investors to digest information that contributes to Microbot Medical's financial success or failures. It also enables traders to predict the movement of Microbot Stock. The fundamental analysis module provides a way to measure Microbot Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Microbot Medical stock.
At this time, Microbot Medical's Interest Expense is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 14.3 M in 2024, despite the fact that Operating Income is likely to grow to (9.4 M). Microbot | Select Account or Indicator |
Microbot Medical Company Return On Asset Analysis
Microbot Medical's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Microbot Medical Return On Asset | -0.65 |
Most of Microbot Medical's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Microbot Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Microbot Total Assets
Total Assets |
|
Based on the latest financial disclosure, Microbot Medical has a Return On Asset of -0.6488. This is 92.59% lower than that of the Health Care Equipment & Supplies sector and 97.76% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Microbot Medical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Microbot Medical's current stock value. Our valuation model uses many indicators to compare Microbot Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Microbot Medical competition to find correlations between indicators driving Microbot Medical's intrinsic value. More Info.Microbot Medical is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Microbot Medical's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Microbot Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Microbot Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Microbot Medical's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Microbot Medical could also be used in its relative valuation, which is a method of valuing Microbot Medical by comparing valuation metrics of similar companies.Microbot Medical is currently under evaluation in return on asset category among its peers.
Microbot Medical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Microbot Medical from analyzing Microbot Medical's financial statements. These drivers represent accounts that assess Microbot Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Microbot Medical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 43.4M | 49.0M | 53.3M | 21.9M | 16.7M | 15.9M | |
| Enterprise Value | 15.5M | 30.2M | 40.5M | 19.9M | 14.5M | 28.5M |
Microbot Fundamentals
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.65 | ||||
| Current Valuation | 12.52 M | ||||
| Shares Outstanding | 16.93 M | ||||
| Shares Owned By Insiders | 1.42 % | ||||
| Shares Owned By Institutions | 7.46 % | ||||
| Number Of Shares Shorted | 565.98 K | ||||
| Price To Earning | (3.42) X | ||||
| Price To Book | 4.40 X | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (10.74 M) | ||||
| Cash And Equivalents | 9.29 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 231 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.60 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (8.53 M) | ||||
| Short Ratio | 2.65 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 16.76 M | ||||
| Total Asset | 8.33 M | ||||
| Retained Earnings | (79.5 M) | ||||
| Working Capital | 4.13 M | ||||
| Current Asset | 15.21 M | ||||
| Current Liabilities | 9.83 M | ||||
| Net Asset | 8.33 M |
About Microbot Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 927.9 K | 1.4 M | |
| Cost Of Revenue | 106 K | 100.7 K | |
| Stock Based Compensation To Revenue | 41.72 | 39.63 | |
| Sales General And Administrative To Revenue | 71.8 K | 75.4 K | |
| Research And Ddevelopement To Revenue | 208.55 | 218.97 | |
| Capex To Revenue | 8.11 | 8.51 | |
| Revenue Per Share | 1.84 | 1.75 | |
| Ebit Per Revenue | (360.92) | (342.88) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.